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Abstract
The MerTK receptor tyrosine kinase is an important negative regulator of dendritic cell function and
is required to prevent B cell autoimmunity in vivo. It is not currently known however, if any causal
relationship exists between these two aspects of MerTK function. We sought to determine if dendritic
cells from mice lacking MerTK (mertk−/− mice) have characteristics that may aid in the development
of B cell autoimmunity. Specifically, we found that mertk−/− mice contain an elevated number of
splenic dendritic cells, and this population contains an elevated proportion of cells secreting the
critical B cell pro-survival factor, B cell activating factor (BAFF). Elevated numbers of BAFF-
secreting cells were also detected among mertk−/− bone marrow-derived dendritic cell (BMDC)
populations. This was observed in both resting BMDC, and BMDC stimulated with
lipopolysaccharide (LPS) or treated with exogenous apoptotic cells. We also found that dendritic
cells in general have a pro-survival effect on resting B cells in co-culture. However, despite containing
more BAFF-secreting cells, mertk−/− BMDC were not superior to C57BL/6 or baff-deficient BMDC
at promoting B cell survival. Furthermore, using decoy receptors, we show that dendritic cells may
promote B cell survival and autoimmunity through a BAFF-and APRIL-independent mechanism.
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INTRODUCTION
Systemic Lupus Erythematosus (SLE) is an autoimmune disease in which a breakdown of
tolerance mechanisms permits self-reactive B cell clones to produce autoantibodies against a
variety of self antigens normally found in the nuclei of intact cells [1]. Numerous single-gene
perturbation mouse models have demonstrated that a wide variety of regulatory mechanisms
exist in both non-B cells and B cells that are necessary to maintain B cell tolerance to nuclear
antigens [2,3]. One such regulatory mechanism involves the members of the TAM (Tyro3,
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Axl, MerTK) family of receptor tyrosine kinases. Mice lacking all three of these receptors
(TAM mice) develop splenomegaly, produce autoantibodies, and exhibit spontaneous
lymphocyte activation, demonstrating that the TAM family is involved in immune homeostasis
and tolerance [4]. Immune dysfunction is also found in mice solely deficient in the mertk gene
(mertk−/− or mertkkd mice). These animals have increased cytokine production [4,5], and
develop autoantibodies to several nuclear antigens targeted in SLE including: dsDNA, ssDNA,
chromatin, and Sm [4,6–8]. Autoimmunity in mertk−/− mice is likely to be primarily driven
by B cell extrinsic mechanisms since MerTK is expressed in macrophage, dendritic cells (DC),
natural killer (NK) cells, NK-T cells, and non-hematopoietic cell types, but is notably absent
from non-malignant B and T cells. [9–12]. This makes mertk−/− mice a valuable model for
examining how B-cell extrinsic mechanisms can facilitate self-reactive B cells to bypass
tolerance safeguards.
The TAM family members play a role in the recognition and phagocytosis of apoptotic cells
[8,13]. Our lab has demonstrated that these receptor TKs are used in different combinations
during the phagocytosis of apoptotic cells depending on the tissue and cell type involved
[13]. Unlike macrophage and retinal pigmented epithelial cells, DC do not require MerTK for
the phagacytosis of apoptotic cells [9,12,13]. Instead, MerTK is used by DC to transduce
inhibitory signals in response to encounters with apoptotic cells. Apoptotic cells render DC
refractory to LPS-induced maturation and inefficient at antigen presentation to T cells [12,
14–16]. Mechanistically, this inhibition proceeds through PI3Kδ and culminates in impaired
activation of the transcription factor NF-κB [12]. Mertk−/− DC lack this inhibitory response
[12].
Dysregulated DC may contribute to the B cell autoreactivity observed in mertk−/− mice. One
mechanism by which DC have the potential to modify B cell behavior is through their
production of the cytokines BAFF (also known as BLyS, TALL-1, and CD257) and APRIL
(A PRoliferation-Inducing Ligand). BAFF is a type II transmembrane protein that contains a
C-terminal cytokine domain which is released upon proteolytic clevage at an extracellular site
[17,18]. Functionally, BAFF and APRIL play a critical role during the middle and later stages
of B cell life history, ranging from the late transitional stages to plasma cells. Perhaps most
important is BAFF’s ability to regulate the size and repertoire of the mature B cell pool by
delivering a necessary pro-survival signal to resting B cells [19–21]. Baff-deficient mice have
severely reduced numbers of mature splenic B cells [22,23], whereas mice carrying a baff
transgene display elevated B cell numbers and signs of autoimmunity [24–26]. Furthermore
BCR-transgenic mouse models have been used to demonstrate that limiting BAFF availability
is a mechanism by which the immune system excludes autoreactive B cell clones from the
mature B cell repertoire [27,28]. In vitro, recombinant BAFF and APRIL promote B cell
survival by activating several pro-survival signaling pathways and down-regulating pro-
apoptotic pathways [29–33].
In contrast to the numerous studies that have focused on BAFF’s effect on B cell physiology,
there is a relative paucity of evidence concerning BAFF production by DC and other cell types.
A small number of studies have shown that DC-derived BAFF can enhance B cell proliferation
[34], plasmablast differentiation [35], Ig class switching [36], and Ig secretion [36,37].
However, direct evidence that DC promote B cell survival, either in vitro or in vivo, via a
BAFF-dependent mechanism is lacking. Furthermore, bone marrow chimera studies involving
baff-null mice have demonstrated that systemic BAFF levels and the maintenance of a normal
B cell compartment require BAFF derived from radiation-resistant (stromal), but not radiation-
sensitive (bone marrow derived), cell populations [38]. Thus the influence that DC-derived
BAFF has on B cell survival in vitro and in vivo is unclear. Also ambiguous is what effect, if
any, the over-production of BAFF by dysregulated DC may have on the survival of nearby B
cells. Intriguingly, splenic DC from TAM mice were recently shown to express elevated levels
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of baff mRNA [39]. However, it is not known whether or not DC lacking individual members
of the TAM family has a similar BAFF expression profile. More importantly, the consequence
of BAFF over-expression by TAM DC in terms of B cell physiology was not investigated.
Given the following observations: 1) mertk−/− mice make autoantibodies, 2) excess BAFF
promotes B cell autoimmunity, 3) DC normally express BAFF, and 4) MerTK functions as a
negative regulator of DC activation, we set out to examine the possibility that MerTK regulates
BAFF production by DCs and therefore influences interactions between DC-B cells. In
agreement with TAM DC [39] we found that DC lacking only MerTK have an enhanced
capacity to secrete BAFF, both at rest and in response to LPS or apoptotic cells. A novel B cell
survival assay was then designed to study the biological significance of DC-derived BAFF.
Unexpectedly, excess BAFF production by mertk−/− DC did not translate into an enhanced
ability to augment B cell survival in vitro. In fact, utilizing baff-deficient animals and decoy
receptors, we found that DC support of B cell survival occurs through a BAFF- and April-
independent mechanism. These results indicate that although MerTK regulates DC BAFF




C57BL/6 mice were purchased from The Jackson Laboratory and then bred in-house.
Mertk−/− mice (known previously as merkd or mertkkd are essentially null mice that do not
express the protein)have been described previously [5,13]. The animals used in these
experiments were backcrossed to C57BL/6 for 6 generations. Mice bearing a homozygous
deletion of the baff gene (baff−/− mice) (also backcrossed to C57BL/6, n=8) were produced
by Dr. Martin Scott and provided by Dr. Susan Kalled (Biogen Idec) [23]. All mice were kept
under pathogen-free conditions in our UNC Division of Laboratory Animal Medicine facilities
and in accordance with the Institutional Animal Care and Use Committee approved protocols.
Autoantibody ELISA assays
For the anti-dsDNA ELISA, calf thymus dsDNA (Promega) was pre-treated with S1 nuclease
(Promega) to remove contaminating ssDNA. Maxisorp plates (NUNC) were then filled with
10 μg of S1-treated dsDNA in 100 μl water, which was evaporated overnight in a 37° oven.
Plates were blocked for 2 hours at room temperature with 4% fetal bovine serum. After
washing, sample sera (diluted 1:100) and standards were added in triplicate and incubated for
2 hours at room temperature. After washing, anti-mouse IgGHRP (R&D Systems) was added
and incubated for 1 hour at room temperature. ABTS (Sigma) was used as a substrate and
absorbance at 405 nm was measured on a microplate reader (Bio-Tek Instruments). The
standard curve consisted of sera pooled from multiple 6 month old MRL/lpr mice. A 1:100
dilution of this serum was arbitrarily designated as 100 Units/ml, 2-fold serial dilutions were
then made down to 1:6400 or 1.56 Units/ml. This was the limit of detection for the assay. A
semi-logarithmic plot was used to derive the standard curve equation (y=mLn(x)+b). The anti-
nucleosome assay was performed as described previously [40].
Ex vivo splenic dendritic cells
DC were enriched from spleens using anti-CD11c microbeads (Miltenyi Biotech) according
to the manufacturer’s instructions. Recovered cells were typically 75–95% CD11c+, as
assessed by flow cytometry.
Gohlke et al. Page 3













Bone marrow-derived dendritic cell (BMDC) culture
To generate DC in vitro, femurs were collected from 2–3 month old mice [41]. Following a
brief ethanol wash and PBS rinse, femurs were flushed with RPMI 1640 (Gibco) to extract
marrow which was then dissociated with gently pipetting. After osmotic red blood cell lysis,
remaining cells were washed in PBS, suspended in media and counted. 2×106 bone marrow
cells were plated in 4 ml of media in 6-well ultra low cluster plates (Corning). BMDC media
consisted of RPMI 1640 containing 10% FBS (Atlanta Biologicals), 50 U/ml penicillin, 50
μg/ml streptomycin, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 0.05 mM β-
Me (all from Gibco), 10 ng/ml GM-CSF and 10 ng/ml IL-4 (both from Peprotech). Cells were
maintained at 37°C with 5% CO2. On day 1 of culture non-adherent cells were removed, diluted
approximately 2-fold with fresh media containing 20 ng/ml GM-CSF and 20 ng/ml IL-4, and
plated in 2 new 6-well ultra low cluster plates. Cultures were fed on day 4 by adding 2 ml of
fresh media containing 30 ng/ml GM-CSF and 30 ng/ml IL-4. On day 7 cultures were fed again
by removing 2 ml of old media and replacing with 2 ml of fresh media containing 30 ng/ml
GM-CSF and 30 ng/ml IL-4. BMDC culture was harvested for experiments on day 8 at which
time CD11c+ cells comprised 85–95% of the culture.
Apoptotic cells
Apoptotic cells were prepared by dissociating mouse thymi in RPMI 1640 and then irradiating
(600 Rads) in a calibrated 137Cs gamma irradiator. Irradiated thymocytes were incubated at
37°C for 12 hours before using in experiments. Apoptosis was confirmed by Annexin V and
propidium iodide staining by flow cytometry.
Flow cytometry
Before staining cells were treated with Fc-block (anti-CD16/CD32) from either BD
Biosciences or Caltag. Cells were then stained with monoclonal antibodies to the following
surface markers where applicable: I-AFITC, CD3FITC, CD11cPE, CD11cPE-Cy7, CD19PE-Cy5,
CD80FITC, CD86FITc. Polyclonal anti-MerTK, and anti-goat IgGPE (both from R&D systems)
were also used. All antibodies were diluted in 1% fetal bovine serum (Atlanta Biologicals).
All washes were done with phosphate buffered saline (Gibco).
BAFF real time RT-PCR
Total RNA was isolated from spleen tissue, ex vivo splenic DC, or cultured BMDC with
TRIZOL reagent (Invitrogen). Further purification, as well as DNase digestion, was carried
out with RNeasy columns (Qiagen). Total RNA was quanitated and then converted to cDNA
using Superscript II reverse transcriptase with random hexamer primers (Invitrogen). cDNA
was used as template in each real-time PCR reaction, which also included 2× Master Mix
(Applied Biosystems) and the following primer/probe sets: baff fwd-primer (5′CCC
AAAACACTGCCCA ACA3′), baff rev-primer (5′CTCATCTCCTTCTTCCAG CCTC3′),
baff TaqMan probe (5′TTCCTGCTACTCGGCTGGCATCG3′) or endogenous control HPRT
fwd-primer (5′GCA AACTTTGCTTTCCCTGG3′), HPRT rev-primer (5′TTCGAGA
GGTCCTTTTCA CCA3′), HPRT TaqMan probe (5′AAGCTTGCAACCTTAACC
ATTTTGGGGCT3′) (all from Applied Biosystems). 96-well reaction plates were run on either
the ABI 7700 or ABI 7500 Real Time PCR machine in the Expression Profiling and SNP
Genotyping Core Facility of the UNC Neuroscience Center. Relative quanitation of baff
expression was made using the comparative 2−ΔΔCt method, with hprt serving as the
endogenous control. This method was validated for equal efficiency of baff and hprt
amplification by a cDNA titration experiment. For the time course measurements of baff
expression in the spleen a total of 5 reactions plates were run. A pool of spleen cDNA from 1-
month old B6 mice was made and served as the calibrator sample on each reaction plate.
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However, each data point in the spleen time course represents 5 mice whose baff expression
was measured independently (unpooled).
BAFF ELISA and ELISPOT assay
The matched pair of monoclonal anti-murine BAFF antibodies 5A8 (capture) and biotinylated
1C9 (detection) from Apotech were used for both the ELISA and ELISPOT assays. ELISA
measuring serum BAFF was carried out according to manufacturer’s instructions in Maxisorp
plates (Nunc). Recombinant murine BAFF (Apotech) was used to generate a standard curve
ranging from 0.75 to 48 ng/ml. Mouse sera were diluted 1:2 and pre-cleared with Protein G
(Amersham) before analysis. For BAFF ELISPOT sterile 96-well Multiscreen plates
(Millipore) were coated at 4°C overnight with 5 μg/ml 5A8 antibody, then washed with PBS
and blocked at room temperature for 2 hours with 1% BSA (Sigma). BMDC were plated at
1×105/well in BMDC media with or without the indicated concentration of LPS (O11:B4,
UltraPure, Invivogen), or with apoptotic cells. In some experiments apoptotic cells were also
pre-incubated with 100nM recombinant murine Gas6 (R&D Systems) and washed three times
in PBS before adding to BMDC. After 3 days plates were washed with PBS, followed by PBS-
tween, then 2 μg/ml biotinylated 1C9 antibody was added and plates incubated overnight at 4°
C. After washing with PBS-tween strepavidin-HRP (BD Biosciences) was added and plates
incubated overnight at 4°C. Plates were developed with 3-amino-9-ethyl carbazole and counted
on an ELISPOT plate reader (CTL).
B cell survival assays
Resting B cells were isolated from mouse spleens by negative selection using a B cell Isolation
kit (Miltenyi Biotec). B cell purity was assessed by flow cytometry to determine CD19
expression and was routinely >95%. B cell survival was assessed on B cell only cultures or B
cell:BMDC cocultures. In some assays B cell survival was enhanced by recombinant BAFF
(Peprotech). This effect could be blocked using soluble BAFFR-Fc or TACI-Fc decoy
receptors, but not a control-Fc reagent (kindly provided by ZymoGenetics).
The B cell:BMDC co-culture was carried out in 24-well Ultra Low Cluster plates (Corning) in
the RPMI-based media described for culturing BMDC. Co-cultures consisted of 5×105 total
cells comprised of varying numbers of B cells and BMDC depending the ratio. For example,
a B cell:BMDC ratio of 4:1 consisted of 4×105 B cells and 1×105 BMDC, while a 16:1 ratio
consisted of 4.71×105 B cells and .29×105 BMDC. In some experiments, BMDC were
stimulated for 20 hours prior to adding to co-culture. For LPS and IFNγ stimulations, upon
harvest, BMDC were prepared for coculture by washing 3 times in PBS (Invitrogen).
Alternatively, when BMDC were treated with fresh apoptotic cells, Lympholyte-M
(Cedarlane) was used to separate apoptotic cells from BMDC prior to using in coculture. In
some experiments TACI-Fc, a BAFF/APRIL decoy receptor, or a control-Fc reagent were
added to coculutre wells at a final concentration of 10 μg/ml. Cocultures were incubated at 37°
in 5% CO2 for 3 days. B cell viability was measured as either the percent of VAD-FMK− B
cells or the absolute number of VAD-FMK− B cells. To determine the absolute number of
viable B cells remaining, first the B cells in each coculture well (distinguished from BMDC
by size and morphology), were counted on a hemocytometer. The percent of viable B cells was
then assessed by staining harvested cells with VAD-FMKFITC (Promega) and CD19PE-Cy5,
followed by analysis on a Cyan flow cytometer (Dako Cytomation). The absolute number of
viable B cells was determined by the following formula:
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Statistical tests were conducted using JMPIN software (SAS Institute). The non-parametric
Wilcoxon Rank-Sum and Kruskal-Wallis tests were used. A p-value of <0.05 was considered
significant.
RESULTS
Elevated anti-nucleosome and anti-dsDNA autoantibody
As mertk−/− mice age they develop progressively elevated titers of autoantibodies to ssDNA
and chromatin [6]. The presence of anti-dsDNA antibodies has also been documented in
mertk−/− mice. However these studies were done at a single time point with a qualitative assay
[8]. To further characterize the pattern of anti-dsDNA, we examined serum from C57BL/6 and
mertk−/− mice at multiple time points using a semi-quantitative assay. We also examined the
pattern of anti-nucleosome antibodies in this same group of animals. Similar to published
findings of other autoantibodies, anti-dsDNA and anti-nucleosome IgG levels were elevated
between 3–6 months of age and steadily increased thereafter (Figure 1).
Elevated numbers of splenic dendritic cells in mertk−/− mice
Autoimmunity in mouse models is frequently associated with enlarged lymphocyte
compartments. Therefore, we next examined whether there were any perturbations in the
composition of splenocyte populations in mertk−/− mice. Surprisingly, the total number of
nucleated splenocytes, as well as the number of B and T cells, were not significantly elevated
in mertk−/− mice at any age tested (Figure 2, A–C). In contrast, CD11c+ I-A+ splenic DC
(spDC) were significantly elevated in mertk−/− mice compared to C57BL/6 counterparts
(Figure 2D). Similar trends were seen when comparing the percentages of these cell types in
the spleens of C57BL/6 and mertk−/− mice: B and T cells were not different, while spDC were
elevated in mertk−/− mice (data not shown).
BAFF is elevated in spleens but not serum of mertk mice
Mertk−/− mice have a defect in the clearance of apoptotic cells [6,8]. Given that the antigens
targeted by autoantibodies in mertk−/− mice are known to be on the surface of apoptotic cells,
and thus exposed to the immune system [42–45], the simplest explanation for autoimmunity
in these mice would be that autoantibodies result from an overabundance of self antigen due
to impaired clearance of apoptotic cells. However, Cohen et al. found that injection of apoptotic
cells into young mertk−/ − mice failed to accelerate the appearance of autoantibodies [6]. This
result argues against the premise that elevated antigen load alone is sufficient to drive
autoimmunity. This led us to question what other age-related changes take place in vivo that
might correlate with the timing of autoantibodies in mertk−/− mice. We first turned our attention
towards the cytokine BAFF. When overexpressed in vivo, BAFF is known to promote
autoantibody production and autoimmune disease. Furthermore, our lab has shown
dysregulated expression of another member of the TNF superfamily, TNF-α, in mertk−/− mice
and macrophages [5].
Initially we set out to determine if age-related changes in baff mRNA or protein levels could
be detected in mertk−/− mice. An analysis of baff mRNA expression in spleen tissue from mice
of varying ages revealed a 2–3 fold increase in spleens from mertk−/− compared to C57BL/6
mice beginning at 6 months of age (Figure 3A). However, serum levels of BAFF protein were
not significantly elevated in mertk−/− mice at any age tested (Figure 3B). When considered in
light of the aforementioned bone marrow chimera studies [38], this data suggests that stromal
cell populations likely produce normal levels of BAFF in mertk−/− mice. However it does not
preclude the possibility that a bone marrow-derived cell type (which does not measurably
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contribute to serum BAFF [38]) may be overexpressing BAFF enough to cause elevated mRNA
levels in the spleens of mertk−/− mice.
BAFF expression in splenic DC from mertk−/− mice
The elevated numbers of DC and elevated baff mRNA transcript levels in the spleens from
mertk−/− mice led us to investigate if mertk−/− spDC produce excess BAFF. In agreement with
recent findings from TAM spDC [39], we found elevated baff mRNA levels in preparations of
spDC taken from mertk−/− mice compared to those from C57BL/6 mice (Figure 3C). The
elevated baff mRNA was predominantly found in spDC from older mertk−/− mice.
Furthermore, when ex vivo spDC were examined for BAFF production by ELISPOT, we found
that a higher frequency of spDC from mertk−/− mice produced BAFF in culture compared to
spDC from C57BL/6 mice (Figure 3D). Unlike baff mRNA expression, elevated BAFF protein
production was most pronounced in the spDC from younger mertk−/− mice. However, the trend
of increased numbers of spDC producing BAFF also held for the older mertk−/− mice when
compared to older C57BL/6 counterparts. Importantly, this was not due to a general increase
in the activation state of these spDC, as surface expression of I-A was similar on spDC taken
from both C57BL/6 and mertk−/− mice (data not shown). These results demonstrate that, in
addition to a larger overall spDC pool in mertk−/− mice, this population contains a higher
frequency of BAFF-producing cells.
If spDC production of BAFF is a contributing factor to B cell autoimmunity in mertk−/− mice
this effect likely occurs locally, rather than globally, since we did not find that systemic BAFF
levels, or B cell numbers, were elevated in mertk−/− mice. To address this further, we compared
the activation state of splenic B cells taken from C57BL/6 and mertk−/− mice, as well as their
expression of BAFFR. Splenic B cells displayed equivalent levels of CD80, CD86, MHC class
II, and BAFFR in C57BL/6 and mertk−/− mice (data not shown). This indicates that elevated
BAFF production by spDC does not cause a global change in B cell physiology in mertk−/−
mice.
Elevated BAFF expression in bone marrow-derived DC
Since baff expression was elevated in spDC from older mertk−/− mice we examined whether
the same was true of bone marrow-derived DC (BMDC) which could be used as a more
obtainable source of DC for further experimentation. In some experiments BMDC were also
generated from baff-deficient (baff−/−) mice as a negative control. We first compared the
efficiency of our BMDC culture method by tracking the differentiation of DC from the various
mouse strains. As shown in Figure 4A, C57BL/6, mertk−/−, and baff−/− BMDC cultures
generated viable CD11c+ cells with similar efficiencies. It was also important to determine
whether the various strains of BMDC possessed similar levels of activation markers in the
immature and mature state. The surface expression of I-A and the costimulatory molecules
CD80 and CD86 was not different among the three genotypes of BMDC, nor was it different
after LPS-induced maturation (Figure 4B). Thus, both mertk−/− and baff−/− BMDC
differentiate similarly and have a similar maturation status to WT BMDC. In terms of their
expression of TAM family members, C57BL/6 BMDC were MerTK+, Axl+, Tyro3−, which is
consistent with a previous report [39]. More importantly, the lack of MerTK does not alter the
expression level of Axl on mertk−/− BMDC (Figure 4C).
Previous reports have demonstrated that DC can be induced to produce BAFF by stimulation
with LPS or IFNγ [18,36]. Therefore, we decided to compare the BAFF-induction response of
mertk−/− and C57BL/6 BMDC by ELISPOT analysis. In the resting state, BMDC populations
lacking mertk contained more BAFF-producing cells than C57BL/6 BMDC (Figure 4D). LPS,
but not IFNγ, stimulation led to a further increase in the number of mertk−/− BMDC that
produced BAFF. Interestingly, neither of these stimuli induced BAFF production by C57BL/
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6 BMDC. While this finding differs from the aforementioned studies using human DC, it is
consistent with previous results using mouse BMDC stimulated with LPS [46].
MerTK functions as a recognition molecule for apoptotic cells by DC. Although MerTK is not
required for the phagocytosis of apoptotic cells by DC [9,12,13], it does alter DC physiology
in response to apoptotic cells by making them refractory to LPS-induced NF-κB activation
[12]. Since others have shown that apoptotic cells can induce BAFF surface expression on DC
[47] we next wanted to see how apoptotic cells affect BAFF production by C57BL/6 and
mertk−/− BMDC via ELISPOT analysis. Once again, in the resting state a proportion of
mertk−/− BMDC spontaneously released BAFF (Figure 4E). This fraction could be nearly
doubled by addition of a 5-fold excess of apoptotic cells to the culture. Apoptotic cells did not
induce BAFF production by C57BL/6 BMDC and did not contribute to background signal in
this ELISPOT assay. These results demonstrate that MerTK is an important negative regulator
of BAFF production in a subpopulation of dendritic cells.
B cell survival is independent of DC-derived BAFF
Given that mertkkd DC produce excess BAFF, we wanted to examine what, if any,
consequences this had on the outcome of interactions between DC and B cells. One of BAFF’s
functions is to provide pro-survival signals for resting B cells [48–51]. We therefore developed
an in vitro assay to monitor the survival of resting B cells. The assay involves culturing splenic
B cells isolated by negative magnetic selection for 3–4 days and then evaluating their viability
using FITC-labeled VAD-FMK. Viability was quantified as either the percentage of B cells
(CD19+) that were VAD-FMK−, or in some experiments, the absolute number of VAD-
FMK− B cells. First the effect of recombinant BAFF (rBAFF) on B cell survival was evaluated
in a titration experiment. In line with previous studies [29,51] rBAFF elevated both the
percentage and absolute number of viable B cells after 4 days in culture (Figure 5A). It appears
that a minimum concentration of 100 ng/ml of rBAFF was necessary to sustain maximum
viability. Using this concentration we found that the pro-survival benefit of BAFF could be
blocked with soluble forms of BAFFR (BAFFR-Fc) or TACI (TACI-Fc, which blocks both
BAFF and APRIL) (Figure 5B).
We next set out to determine if BMDC could enhance the survival of resting B cells. Compared
to B cells cultured alone, the presence of either C57BL/6 or mertk−/− BMDC in the culture
increased the absolute number of VAD-FMK− B cells (Figure 6A). Unexpectedly, culturing
B cells with mertk−/− BMDC did not result in greater viability compared to those cultured with
C57BL/6 BMDC, although very few viable B cells remained in the absence of BMDCs.
Furthermore, fixing BMDC with paraformaldehyde prior to adding to the B cell culture
prevented BMDC augmentation of B cell survival, demonstrating that this phenomenon is an
active process that requires living BMDC (data not shown). When BMDC were pre-stimulated
with LPS or apoptotic cells to increase the number of BAFF-producing cells, mertk−/− BMDC
still did not outperform C57BL/6 BMDC (Figure 6B). Thus, despite producing excess BAFF,
mertk−/− BMDC do not provide enhanced survival signals to neighboring B cells. In agreement
with this, baff−/− BMDC performed similarly to C57BL/6 and mertk−/− BMDC in supporting
the survival of B cells (Figure 6B).
These results point towards the existence of a BAFF-independent mechanism by which DC
enhance B cell survival. APRIL is another TNF family member that is closely related to BAFF.
It too is produced by dendritic cells and causes some, but not all, of the same effects on B cells
that BAFF does. The exact role that APRIL plays in B cell survival is unclear since mice lacking
APRIL do not display the same deficit in total B cells that baff−/− mice do. Furthermore, while
APRIL and BAFF both use the BCMA and TACI receptors, APRIL does not bind to BAFFR,
which is the critical receptor for mediating the B cell survival function of BAFF. Nevertheless,
it is possible that the ability of BMDC to promote B cell survival independent of BAFF is due
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to BMDC production of APRIL. To test this we added the soluble form of the TACI receptor
(TACI-Fc), or a control-Fc reagent, to our co-culture system. As can be seen in Figure 6C,
simultaneous block of APRIL and BAFF function with the TACI-Fc decoy receptor did not
reduce the ability of C57BL/6 and mertk−/− BMDC to support B cell survival compared to co-
cultures treated with the control-Fc reagent. This result suggests that BMDC promotion of
resting B cell survival is independent of both BAFF and APRIL.
DISCUSSION
MerTK is a cell surface receptor tyrosine kinase which functions as an apoptotic cell
recognition molecule and a negative regulator of cell activation on dendritic cells [12]. Given
that DC have the ability to influence autoreactive B cell responses [52–55] we sought to
determine if DC lacking MerTK have characteristics that would be consistent with
autoimmunity in mertk−/− mice. In support of this we found that a sub-population of cells
spontaneously produced the B cell pro-survival cytokine BAFF exists among spDC and BMDC
populations from mertk−/− mice. We were also able to demonstrate that BMDC are able to
influence the survival of neighboring B cells. Unexpectedly, however, this phenomenon is not
influenced by the absence of mertk or baff expression by DC.
The data presented in this study demonstrates that MerTK has a role in regulating DC
physiology in vitro as well as in vivo. We found that mertk−/− mice contain an elevated number
of splenic DC. This finding has relevance to autoimmunity because DC made resistant to
apoptosis by genetic manipulation can promote autoantibody production in susceptible mouse
strains [53]. It is unclear, however, if MerTK is influencing the survival of DC within the spleen
[56] or affecting the size of this population in other ways. For example, there may be increased
output of DC progenitors from the bone marrow [57], or altered differentiation of blood
monocytes or DC precursors into spDC [58–61]. It is interesting that serum from SLE patients
has the ability to induce DC differentiation from monocytes in vitro [62]. This was shown to
be IFN-α dependent process so it will be informative to determine what the circulating IFN-
α levels are in mertk−/− mice.
Despite our findings of a potential role for MerTK in regulating the size of the splenic DC pool,
it is also important to point out that splenic DC numbers were not elevated when the
mertk−/− allele was moved onto the non-obese diabetic (NOD) genetic background by marker-
assisted backcrossing [63]. Our mertk−/− allele is on the C57BL/6 genetic background (n=6).
It will be interesting to see if our observations regarding splenic DC numbers persist in mice
backcrossed additional generations. The difference between these outcomes may suggest that
MerTK’s role in regulating splenic DC populations is dependent upon its interactions with
specific alleles (NOD vs. C57BL/6) of other genes.
Despite the increase in spDC number seen in both young and old mertk−/− mice autoantibody
production in mertk−/− mice does not begin until later in life. This suggests that some other
factor exists that precipitates a breakdown in B cell tolerance in older mice. We found elevated
levels of baff mRNA in spleen tissue from mertk−/− mice beginning at 6 months of age.
However, this increase was not sufficient to cause an increase in circulating systemic BAFF.
This is not inconsistent with a role for MerTK in regulating BAFF production by selected cell
types of the immune system since detectable levels of systemic BAFF are produced exclusively
by non-hematopoetic cell types [38]. Our finding of WT levels of serum BAFF in mertk−/−
mice (Figure 3B) is also consistent with their normal B cell numbers (Figure 2B), since this
population is expanded when BAFF levels are systemically elevated [64,65]. Interestingly,
SLE patient clinical disease scores and autoantibody levels are significantly correlated with
blood leukocyte baff mRNA levels, but not with serum BAFF protein levels [66]. This fits a
model in which myeloid-lineage cells, while not able to contribute significantly to the pool of
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serum BAFF, are still able to influence B cell survival and tolerance locally via the production
of BAFF.
We chose to examine DC as a source of BAFF, as opposed to other MerTK-expressing cell
types, specifically because of their role in interacting with and activating antigen-specific B
cells [35,67–69]. Recently spDC from mice lacking all three TAM family members were shown
to have elevated baff mRNA expression levels [39]. While this demonstrates that as a family,
MerTK, Axl, and Tyro3 have a net inhibitory role on BAFF production, we clarify these results
by showing that the lack of mertk alone is sufficient to cause elevated baff mRNA in spDC
(Figure 3C). Moreover, we were able to confirm this data at the protein level by showing that
spDC in mertk−/− mice harbor a population of cells that spontaneously release BAFF protein
ex vivo (Figure 3D). Given that mertk−/− mice have a larger DC population comprised of an
elevated proportion of BAFF-producing cells, DC may be participants in autoantibody
production in mertk−/− mice. However, it is also important to consider other cell types that
might be involved. Macrophages for example, also express MerTK, BAFF and APRIL, and
populate similar anatomical locations in the spleen as DC [13,18,34,70,71]. To investigate
whether dysregulated BAFF expression by DC specifically is sufficient to drive B cell
autoimmunity in mertk−/− mice, we are currently generating a conditional baff−/− mouse. Since
there are two non-redundant pools of baff-producing cells (hematopoetic and stromal) [38] our
conditional baff−/− mouse will be very useful in delineating the sources of BAFF relevant to
protective and pathogenic humoral immune responses.
To further our understanding of how MerTK regulates DC BAFF production we used BMDC
cultures. We found that C57BL/6 BMDC produced very little BAFF, even in the presence of
LPS or IFNγ. In keeping with MerTK’s role as an inhibitory molecule in DC physiology [12]
we found that MerTK is a negative regulator of BMDC BAFF production. However, in contrast
to other MerTK-regulated DC activities such as the inhibition of NF-κB activation, the
importance of MerTK in controlling BAFF production is apparent even in the absence of
exogenous stimuli. The number of BAFF-producing mertk−/− BMDC could be further
increased in the presence of LPS. Thus, BAFF secretion is tightly regulated in mouse DC, and
MerTK may be a participant in this regulatory mechanism. Importantly, both C57BL/6 and
mertk−/− BMDC upregulate MHC class II, CD80 and CD86 to a similar degree in the presence
of LPS. This demonstrates that the C57BL/6 BMDC are not refractory to stimulation in general,
and that the reduced control over BAFF-production by mertk−/− BMDC is not simply due to
a general heightened activation state. It should be mentioned that a previous report
demonstrated elevated levels of CD80, CD86, and MHC class II on spDC from TAM mice
[4]; however, the triple mutant mice used in that study had a heterogeneous genetic background,
as opposed to our C57BL/6-backcrossed mertk−/− mice. Moreover, our results on this issue
are consistent with data obtained by Roland Tisch’s group using NOD. mertk−/− mice [16,
63].
Apoptotic cells deliver a negative signal to DC by preventing LPS- or CD40L-induced
activation of the NF-κB signaling pathway by a MerTK-dependent mechanism [12].
Surprisingly we found that, rather than conveying an inhibitory effect, apoptotic cells increased
the proportion of BAFF-producing mertk−/− BMDC. C57BL/6 DC can be prompted to release
BAFF by immune complexes of chromatin and IgG [46]. This response may partly explain our
experimental results given that chromatin is exposed on the surface of apoptotic cells [45].
However the lack of a positive BAFF response to apoptotic cells by C57BL/6 BMDC in our
experiments suggests that an inhibitory mechanism exists to prevent BAFF release by DC upon
encounter with apoptotic cells, but presumably is not involved in inhibiting the response to
IgG-bound chromatin. The positive BAFF response by mertkkd BMDC suggests that MerTK
may be involved in this proposed inhibitory mechanism such that during an encounter with
apoptotic cells BAFF-induction signals are provided to DC unimpeded.
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DC are known to capture, recycle, and display antigens in a way that preserves their epitopes
for recognition by cognate B cells [67–69,72]. While this “native antigen presentation” has yet
to be demonstrated for material derived from apoptotic cells, DC pre-fed apoptotic cells are
efficient at inducing anti-nuclear antibodies upon injection into C57BL/6 mice, suggesting that
antigen was made accessible to B cells [52,54]. Therefore, our finding that apoptotic cells can
deliver a BAFF induction signal to DC contributes to the existing literature by raising the
possibility that DC which have engulfed apoptotic cells are capable of providing both intact
self-antigen and BAFF to autoreactive B cells.
We also found that BMDC have a pro-survival effect on neighboring B cells in culture.
Unexpectedly, this involves a BAFF-independent mechanism, perhaps involving APRIL, since
culturing B cells with either C57BL/6 BMDC, which produce very little BAFF under all
conditions tested, or with baff−/− BMDC resulted in similar numbers of viable B cells compared
to those cultured with mertk−/− BMDC which contain a higher frequency of BAFF-producing
cells. The augmentation of B cell survival by BMDC may involve other secreted factors (e.g.
APRIL) or signals delivered via cell-cell contact. Interestingly, autoantibody production still
occurs in lupus-prone New Zealand Mixed 2328 mice bearing a homozygous deletion of the
baff gene (NZM.baff−/−) [73], though no one has yet crossed this strain to APRIL-deficient
mice. Our in vitro data demonstrating that DC-mediated enhancement of B cell survival is
BAFF-independent could offer a mechanistic explanation for the persistent autoimmunity seen
in NZM.baff−/− mice.
This is the first study involving DC from baff-deficient mice. Our results illustrate how much
there is yet to learn about the importance of DC-derived BAFF and APRIL during in vitro and
in vivo interactions with B cells. Although DC-derived BAFF is not necessary to promote B
cell survival, it may play an important role in the differentiation of antigen-stimulated B cells
into antibody-secreting cells.
In summary, we have found that DC production of the BAFF cytokine is regulated by the
receptor tyrosine kinase MerTK. In the absence of MerTK, there is an increase in baff mRNA
expression in the spleen and among spDC from mertk−/− mice. Furthermore, BAFF is
constitutively produced by a proportion of mertk−/− BMDC at rest, while more BMDC can be
recruited into the BAFF-producing pool by treatment with LPS or apoptotic cells. However,
this excess BAFF production capacity does not translate into improved viability of neighboring
B cells. Thus, the augmentation of resting B cells survival by BMDC in vitro is independent
of BAFF and MerTK. It remains to be determined whether MerTK, BAFF and APRIL influence
DC-mediated B cell activation, plasma cell differentiation and autoantibody production.
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Figure 1. Anti-nucleosome and Anti-dsDNA Antibodies Increase in mertk−/− Mice with Age
Levels of anti-nucleosome (A) and anti-dsDNA (B) antibodies were measured by ELISA in a
cohort of C57BL/6 (○) and mertk−/− (▲) mice. The dotted line represents the limit of detection
in each assay. These limits are 15 ng/ml and 1.56 Units/ml for the anti-nucleosome and anti-
dsDNA assays, respectively. Statistical significance was determined by Wilcoxon Rank Sum
test at each time point (* p<0.05, ** p<0.001, *** p<0.005).
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Figure 2. Spleens of mertk−/− Mice Contain Elevated Numbers of Dendritic Cells
Shown are the numbers of total nucleated splenocytes (A), splenic B cells (B), splenic T cells
(C), and splenic dendritic cells (D) from C57BL/6 (□) and mertk−/− (▲) mice of various ages.
Sample flow cytometry plots showing the gating scheme used to measure the various cell types
are also shown (R1=B cells, R2=T cells, R3=Dendritic Cells). Total numbers of a specific
population for a given mouse were calculated by multiplying the total number of nucleated
splenocytes by the percentage of those cells falling within the assigned gate. Statistical
significance of differences between cell populations from C57BL/6 and mertk−/− mice was
determined by the Wilcoxon Rank Sum test, the results of which are shown to the right of each
graph title (ns, not significant, * p<0.05).
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Figure 3. Splenic DC from mertk−/− Mice Produce Excess BAFF
A) Real time PCR analysis of baff mRNA expression in the spleen. Each data point represents
the mean expression (± sem) in the spleen of five C57BL/6 (□) or mertk−/− (▲) mice from the
indicated age group. B) ELISA analysis of serum BAFF levels in C57BL/6 (□) or mertk−/−
(▲) mice (n = 3–7 mice per group. Horizontal lines depict the mean of each group. C) Real
time PCR analysis of baff mRNA expression in splenic DC (spDC) isolated from C57BL/6
(open bars) or mertk−/− (filled bars) mice. Each bar represents the mean value (± sem) of pooled
data from spDC isolated from 4–5 different mice. D) ELISPOT analysis of ex vivo BAFF
secretion by spDC isolated from young and old C57BL/6 (□) and mertk−/− (▲) mice. Each
data point represents the number of BAFF spots counted (mean ± sem) from four wells
containing spDC from a single donor mouse. Horizontal lines represent the mean number of
BAFF spots for the 3 donor mice in each group. In both (C) and (D) “Young” mice were 2–3
months of age, while “Old” mice were 10–14 months of age. Statistical significance was
determined using the Wilcoxon Rank Sum test ( p<0.05).
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Figure 4. BMDC Cultures Generated from mertk−/− Mice Spontaneously Produce BAFF in vitro
A) Bone Marrow-Derived Dendritic Cell (BMDC) cultures from C57BL/6 (□, dotted line),
mertk−/− (▲, solid line), and baff−/− ( , solid gray line) mice were compared in their ability
to generate CD11c+ cells (left) and the viability of CD11c+-gated cells (right). Culture
conditions were as described in Materials and Methods section with the exception that volumes
and starting cell numbers were scaled down to accommodate 24-well Ultra Low Cluster plates.
Each data point represents the mean (± sem) measurement from three culture wells. Data is
representative of three experiments. B) C57BL/6, mertk−/− and baff−/− BMDC were cultured
in media alone (solid line) or with 500 ng/ml LPS (dotted line) for 2 days, after which time
surface expression of I-A, CD80 and CD86 was analyzed by flow cytometry. Appropriate
isotype control staining is also shown (gray fill). Data is representative of 2–4 experiments per
genotype. C) C57BL/6 and mertk−/− BMDC were stained with antibodies against MerTK, Axl,
or Tyro3 (solid lines) and the appropriate isotype control (gray fill). All histograms are gated
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on CD11c+ events. D and E) The number of BAFF-producing cells within C57BL/6 (open
bars), mertk−/− (black bars) and baff−/− (gray bars) BMDC cultures responding to LPS (500
ng/ml) or IFNγ (100U/ml) (D), or apoptotic cells (E) was measured by ELISPOT. In (E) BMDC
were treated with an equal number (1X) or 5-fold excess (5X) of apoptotic cells (AC). Data
from wells containing only apoptotic cells is also shown. Each bar represents the mean (± sem)
of three ELISPOT culture wells. Data is representative of three independent experiments.
Statistical significance within each treatment group was determined by the Kruskal-Wallis test
(* p<0.05).
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Figure 5. A Novel Assay for Measuring B Cell Survival in Vitro
A) B cells were isolated from splenocyte populations of C57BL/6 mice by negative magnetic
selection. 2×105 B cells were then cultured with rBAFF (500 ng/ml, 100 ng/ml, 20 mg/ml, 4
ng/ml) or media alone for 4 days. Harvested cells were counted and the percent viability among
CD19+ events was determined by staining with VAD-FMKFITC. Data (mean ± sem) is plotted
as either the percent of VAD-FMK− B cells (left) or the absolute number of viable B cells
remaining (right). A sample flow cytometry plot showing how viable B cell populations (VAD-
FMK−, gate R1) were identified from within cultured B cells is also shown. B) B cells were
cultured in 100 ng/ml rBAFF plus 500, 50, 5, 0.5, 0.05, or 0.005 μg/ml of the soluble decoy
receptors BAFFR-Fc (▲) or TACI-Fc (□), or a control-Fc reagent (grey ●). For comparison
B cells cultured without decoy Fc reagents in either 100 ng/ml rBAFF (◆), or media alone
(◇) are also shown (right). After 3 days the viability was measured by VAD-FMK staining
of CD19+ events. Results from one of two independent experiments are shown.
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Figure 6. BMDC Provide Pro-Survival Signals to Resting B Cells
A) 4×105 negatively-selected B cells were cultured alone (striped bar) or with 1×105
unstimulated C57BL/6 (open bar) or mertk−/− (black bar) BMDC for 3 days at which time the
absolute number viable B cells was determined as described in Materials and Methods. Data
bars represent the mean (± sem) of 3 culture wells. Data is representative of two independent
experiments. Statistical significance of survival differences between B cells cultured with
BMDC versus those cultured alone was determined using the Wilcoxon Rank Sum test (*
p<0.05). B) C57BL/6 (open bars), mertk−/− (black bars), and baff−/− (grey bars) BMDC were
pre-treated as indicated for 24 hours before washing and culturing with B cells as described
above. B cells were also cultured alone (striped bar, “no BMDC”). Each well contained
4×105 B cells and 1×105 BMDC. Data bars represent the mean (± sem) of 3 culture wells.
There were no statistically significant differences between BMDC genotypes within each
treatment group as determined by the Kruskal-Wallis test. Data is representative of two
independent experiments. C) Co-culutres containing resting B cells, untreated C57BL/6 (open
bars) or mertk−/− (black bars) BMDC, and 10 μg/ml of either TACI-Fc or Control-Fc soluble
decoy receptors were established as described above. B cells were also cultured alone (striped
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bar, “no BMDC”). After 2 days the number of viable B cells was determined as above. Data
bars represent the mean (± sem) of 3 culture wells. There were no statistically significant
differences between BMDC genotypes or between the TACI-Fc and control-Fc treated groups
as determined by the Wilcoxon Rank Sum test.
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